Obalon Therapeutics

About Obalon Therapeutics

Obalon Therapeutics, Inc. is a medical technology company specializing in innovative weight loss solutions. The company's flagship product, the Obalon Balloon System, is the first and only swallowable, FDA-approved, three-balloon system designed to aid weight loss in adults with obesity. This system is specifically targeted at individuals with a Body Mass Index (BMI) of 30-40 kg/m² who have not achieved significant weight loss through diet and exercise alone.

The Obalon Balloon System works by occupying space in the stomach, which helps patients feel full sooner and eat less. The system is intended to be used alongside a moderate-intensity diet and behavior modification program. Each balloon is swallowed in a capsule form and then inflated in the stomach. All balloons must be removed six months after the first balloon is placed. This approach has shown promising results, with an average of 89% of weight loss maintained six months after the balloons are removed, provided the patient continues with a diet and exercise regimen.

Obalon operates in the healthcare and medical devices market, focusing on the obesity treatment segment. The company primarily serves adults struggling with obesity who are looking for non-surgical weight loss solutions. The business model revolves around the sale of the Obalon Balloon System to healthcare providers, who then offer the treatment to patients. Revenue is generated through the sale of these balloon systems and associated medical services.

In summary, Obalon Therapeutics provides a unique, minimally invasive weight loss solution that helps patients achieve and maintain significant weight loss. The company leverages its innovative technology to address a critical need in the obesity treatment market, offering a viable alternative to more invasive surgical procedures.